Crossmark

A non-canonical SWI/SNF complex is a synthetic lethal target in cancers driven by BAF complex perturbation

Crossref DOI link: https://doi.org/10.1038/s41556-018-0221-1

Published Online: 2018-11-05

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Michel, Brittany C.

D’Avino, Andrew R.

Cassel, Seth H.

Mashtalir, Nazar

McKenzie, Zachary M.

McBride, Matthew J.

Valencia, Alfredo M.

Zhou, Qianhe

Bocker, Michael

Soares, Luis M. M.

Pan, Joshua http://orcid.org/0000-0002-7745-1497
Remillard, David I.

Lareau, Caleb A. http://orcid.org/0000-0003-4179-4807
Zullow, Hayley J.

Fortoul, Nora

Gray, Nathanael S.

Bradner, James E.

Chan, Ho Man

Kadoch, Cigall http://orcid.org/0000-0002-4058-5985
License Information

Text and Data Mining valid from 2018-11-05
More Information

Article History

Received: 4 July 2018

Accepted: 21 September 2018

First Online: 5 November 2018

Competing interests

: C.K. is a scientific founder, fiduciary Board of Directors member, Scientific Advisory Board (SAB) member, shareholder and consultant for Foghorn Therapeutics, Inc. (Cambridge, MA). H.M.C., Q.Z, M.B. and L.M.M.S are employees and shareholders of Foghorn Therapeutics, Inc. (Cambridge, MA). N.S.G. is a scientific founder, SAB member and equity holder in Gatekeeper, Syros, Petra, Soltego and C4 Therapeutics. J.E.B is now an executive and shareholder of Novartis AG. He is a founder and former shareholder of Tensha Therapeutics (a bromodomain company, now Roche) and Syros (a chromatin biotech). The other authors declare no competing interests.